Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

Participation Type:

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 26 of 26 from AIDS Vaccine 2012
Opening Session
Dan Barouch
Conference Chair, Boston, MA United States of America
Amit Dixit
Boston, MA United States of America
Galit Alter
Conference Chair, Boston, MA United States of America
Bill Snow
Global HIV Vaccine Enterprise, New York, NY United States of America
A Memorial Tribute to Dr. Norman Letvin
Gary Nabel and Bart Haynes
Vaccine Research Center and Duke Human Vaccine Institute, USA
Integrating AIDS Prevention and Care in Haiti and Rwanda: A Clinician's View
Paul Farmer
Harvard Medical School, Boston, MA United States of America
Trevor Mundel
Bill & Melinda Gates Foundation, Seattle, WA United States of America
from AIDS Vaccine 2012 on 9 September 2012 4:30 PM-6:30 PM
Plenary Session 01: HIV Vaccines in the Broader HIV Prevention Landscape
An HIV Vaccine in the Context of a Combination Non-Vaccine Prevention Program
Anthony Fauci
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD United States of America
Welcome by Governor Deval Patrick
Governor Deval L. Patrick
Boston, MA United States of America
The current state of microbicides as prevention
Salim Abdool Karim
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
Oral PrEP for HIV Prevention: Next Steps
Jared Baeten
University of Washington, Seattle, WA United States of America
ART for Prevention of HIV: Glimmers of Success
Myron Cohen
University of NC at Chapel Hill, Chapel Hill, NC United States of America
from AIDS Vaccine 2012 on 10 September 2012 8:30 AM-10:30 AM
Oral Abstract 01: Animal Models
Significant Protection from Infection and AIDS Progression After Gastrointestinal and Oral Vaccinations, Respectively, with a SIV DNA/rMVA Vaccine
Anna Aldovini
Children's Hospital Boston, Harvard Medical School, Pediatrics, Boston, MA United States of America
Antibodies to the Envelope Protein Protect Macaques from SIVmac251 Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial
Genoveffa Franchini
NCI/NIH, Bethesda, MD United States of America
Immune Control of an SIV Challenge by a Heterolgous and Direct Mucosal Vaccination Regimen in Rhesus Monkeys
Linqi Zhang
Comprehensive AIDS Research Center, Tsinghua University, Beijing, China
A Recombinant Attenuated Mycobacterium Tuberculosis-SIV Combination Vaccine Is Safe and Immunogenic in Immunocompromised, SIV-Infected Infant Macaques
Kristina Abel
UNC Chapel Hill, Microbiology and Immunology, and CFAR, Chapel Hill, NC United States of America
MAb PGT121 Protects Against Mucosal SHIV Challenge in Macaques at Concentrations Corresponding to Its Highly Potent In Vitro Neutralization Capacity
Brian Moldt
The Scripps Research Institute, La Jolla, CA United States of America
Epitope Specificity Appears to Be an Important Determinant of In Vivo Killing Ability of Simian Immunodeficiency Virus (SIV)-Specific CD8+ T Cells
Lu-Ann Pozzi
Harvard Medical School, Immunology, Southborough, MA United States of America
from AIDS Vaccine 2012 on 10 September 2012 11:00 AM-12:30 PM
Oral Abstract 02: Vaccine Concepts - Protein Immunogens
Identification of a Clade A HIV Envelope Immunogen from Protocol G That Elicits Neutralizing Antibodies to Tier 2 Viruses
Simon Hoffenberg
International AIDS Vaccine Initiative, Brooklyn, NY United States of America
Prime-Boost Regimen Potency and Efficacy with Alphavirus Replicons (SIV Antigen) in Non-human Primates Challenged with Low-Dose Intra-rectal SIVsmE660
Kaustuv Banerjee
Novartis Vaccines and Diagnostics, Cambridge, MA United States of America
Minimally Invasive and Surface Electroporation Delivery of DNA Vaccines for the Induction of Robust Humoral Immune Responses Against HIV Antigens
Niranjan Y. Sardesai
Inovio Pharmaceuticals, Blue Bell, PA United States of America
Design of Lipid Nanoparticle Delivery Agents for Multivalent Display of Recombinant Env Trimers in HIV Vaccination
Sharmila Pejawar-Gaddy
Massachusetts Institute of Technology, Boston, MA United States of America
Eliciting Neutralizing Antibodies with gp120 Outer Domain
Yali Qin
Iowa State University, Biomedical Sciences, Ames, IA United States of America
Oral immunization with a recombinant Lactococcus lactis expressing HIV-1 Gag on the tip of the pilus induces strong mucosal immune responses
Venkateswarlu Chamcha
Emory University, Department of Microbiology and Immunology, Yerkes National Primate Res, Atlanta, GA United States of America
from AIDS Vaccine 2012 on 10 September 2012 11:00 AM-12:30 PM
Oral Abstract 03: Innate Immunity
SIV?nef Vaccination Mobilizes Systemic and Mucosal Natural Killer Cells in Mamu A*01+ Macaques
R. Keith Reeves
NEPRC, Harvard Medical School, Southborough, MA United States of America
RV144-like Trial in Macaques Using ALVAC-SIV & gp120, Induces Innate Immunity and Increases the Frequency of NK22 & NKG2A+ Cells in Mucosal Tissues
Namal P.M. Liyanage
Animal Models & Retroviral Vaccines Section , National Cancer Institute, NIH, Bethesda, MD United States of America
Adenovirus Vectors from Various Serotypes Induce Distinct Cytokine Profiles
Jeffrey E. Teigler
Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA United States of America
Infiltration of Dendritic Cells and Antigen Uptake in the Muscle After Injection of HIV-1 Env gp120 in Adjuvant
Karin Loré
Karolinska Institutet, Dept of Medicine, Stockholm, Sweden
Early Pro-inflammatory Host Response to Recombinant HSV-SIV Vaccination in Sooty Mangabeys
Namita Rout
NEPRC-HMS, Immunology, Southborough, MA United States of America
Vaccination with MVA/HIV induces differential recruitment of monocyte subsets into the circulation and monocyte-specific transcriptional programs
Erica Andersen-Nissen
Fred Hutchinson Cancer Research Center, VIDD, Seattle, WA United States of America
from AIDS Vaccine 2012 on 10 September 2012 11:00 AM-12:30 PM
Oral Abstract 04: Mucosal Immunity
Immune Complexes Can Dampen Inflammatory Signaling at the Mucosal Surface During Protective SIV Vaccination
Anthony J. Smith
University of Minnesota , Minneapolis, MN United States of America
Vaccine-Elicited Systemic and Mucosal Humoral Responses of Lactating Rhesus Monkeys Vaccinated with the Transmitted/Founder HIV Envelope 1086C
Sallie R. Permar
Duke University Medical Center, Pediatrics, Durham, NC United States of America
Expanded Memory CD4+ T Cells in the Fetal and the Infant Gut; a Mucosal Route for Mother-to-Child-Transmission of HIV-1
Madeleine J. Bunders
Academic Medical Centre, Department of Pediatric Hematology, Immunology and Infectious Diseases, Amsterdam, Netherlands
Cell Free HIV-1 Virus Can Infect Inner and Outer Foreskin Polarized Explants
Maria P. Lemos
Fred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, WA United States of America
Inflammation in the Male Genital Tract: Implications for HIV Acquisition and Transmission
Abraham J. Olivier
IIDMM, Division of Medical Virology, University of Cape Town, Clinical Laboratory Sciences, Cape Town, South Africa
from AIDS Vaccine 2012 on 10 September 2012 1:30 PM-2:45 PM
Oral Abstract 05: Social/Ethical Issues
An Assessment of Good Participatory Practice Guidelines at HIV Prevention Research Clinical Centers in Eastern and Southern Africa
Prince Bahati
International AIDS Vaccine Initiative, East Africa Regional Office, Nairobi, Kenya
New Tools to Measure Community and Stakeholder Engagement and Its Impact on Outcomes of Clinical Research
Stacey Hannah
AVAC, New York, NY, United States of America
Social and Ethical Considerations in Engaging American Indian and Alaska Native Communities in HIV Clinical Research
Jessica Velcoff
Fred Hutchinson Cancer Research Center, Legacy Project, Seattle, WA United States of America
Knowledge/attitude/practices of HPV & cervical cancer, willingness to participate in vaccine trial in preparation for HIV & HPV vaccine trials in Mali
Danielle Poole
Brown University, Providence, RI United States of America
Referral and Access to Care of HIV Prevalent Cases; Experience from the Early Capture HIV Cohort Study in Kampala
Lillian N. Mutengu
Makerere University Walter Reed Project, Community Outreach , Kampala, Uganda
from AIDS Vaccine 2012 on 10 September 2012 1:30 PM-2:45 PM
Oral Abstract 06: V1/V2 Antibody Responses
A Short Segment in the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Neutralization Resistance to PG9-Like Antibodies
Nicole A. Doria-Rose
National Institutes of Health, Bethesda, MD United States of America
Characterization of V1V2-Specific Antibodies Present in Broadly Neutralizing Plasma Isolated from HIV-1 Infected Individuals
Abe Pinter
UMDNJ, Newark, NJ, United States of America
Design of an HIV Env Antigen That Binds with High Affinity to Antibodies Against Linear, Conformational and Broadly Neutralizing Epitopes Within V1/V2
Larry (Huaxin) Liao
Duke University Medical Center, Duke Human Vaccine Institute, Durham, NC United States of America
Evidence for Env-V2 Sieve Effect in Breakthrough SIVMAC251 Infections in Rhesus Monkeys Vaccinated with Ad26/MVA and MVA/Ad26 Constructs
Morgane Rolland
MHRP, HJF, Bethesda, MD United States of America
Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120
Anthony P. West, Jr.
California Institute of Technology, Division of Biology, Pasadena, CA United States of America
from AIDS Vaccine 2012 on 10 September 2012 1:30 PM-2:45 PM
Symposia 01: Exploiting the Innate Immune Response
Development of Dendritic Cell-based Prophylactic and Therapeutic HIV Vaccine
Yves Levy
CHU Henri Mondor, Creteil, France
Adjuvants Influence the Magnitude, Quality and Durability of HIV Env Specific Humoral Immunity in Non-human Primates
Robert Seder
Vaccine Research Center, National Institutes of Health, Bethesda, MD United States of America
Systems Analysis of HIV Vaccine Triggered Innate Immune Responses
Daniel Zak
Seattle BioMed, Seattle, WA United States of America
Profiling Humoral Immunity: Determining Antibody Innate Immune Recruiting Capacity
Margaret Ackerman
Thayer School of Engineering, Hanover, NH United States of America
Natural Killer (NK) Cell Responses at Female Genital Mucosa to SIV Vaginal Challenge
Liang Shang
University of Minnesota, Minneapolis, MN United States of America
from AIDS Vaccine 2012 on 10 September 2012 4:00 PM-6:00 PM
Symposia 02: Lessons from Clinical Trials
RV144 Update: Insights from Correlates of Risk, Breakthrough Infections, and Animal Studies in the Context of Future Vaccine Development
Jerome Kim
Walter Reed Army Institute of Research (WRAIR), Rockville, MD United States of America
Comparative Immunogenicity of HIV Vaccine Candidates in the HVTN
Nicole Frahm
Fred Hutchinson Cancer Research Center, Seattle, WA United States of America
Clinical Studies with Adenovirus 26 Vectored Candidate HIV-1 Vaccines.
Raphael Dolin
Beth Israel Deaconess Medical Center, Boston, MA United States of America
HIV Immunity and Reservoir Following Interventions in Acute HIV Infection: Implication for Functional Cure
Jintanat Ananworanich
SEARCH, The Thai Red Cross AIDS Research Centre; INCOMPLETE, Bangkok, Thailand
Vector Induced Skewing of Antibody Fc-effector Functions
Amy Chung
Ragon Institute of MGH, MIT & Harvard, Boston, MA United States of America
from AIDS Vaccine 2012 on 10 September 2012 4:00 PM-6:00 PM
Symposia 03: New Env Immunogens
Structural Basis for HIV-1 Trimeric Env Immunogen
Youdong Mao
Dana-Farber Cancer Institute, Boston, MA United States of America
Pure Native Env Trimers on VLP Surfaces and in Soluble Form.
James M. Binley
TPIMS, San Diego, CA United States of America
Envelope Immunogen: Stable and Homogeneous HIV-1 gp140 Trimers
Bing Chen
Children's Hospital Boston/Harvard Medical School, Boston, MA United States of America
Epitope-focused Vaccines
William Schief
International AIDS Vaccine Initiative and The Scripps Research Institute, La Jolla, CA United States of America
Eliciting Broadly Neutralizing Antibodies Against HIV-1 that Target gp41 MPER.
Michael W. Cho
Iowa State University, Ames, IA United States of America
from AIDS Vaccine 2012 on 10 September 2012 4:00 PM-6:00 PM
Plenary Session 02: A New Look at the Transmission Event
Barriers to Mucosal transmission: challenges and opportunities
Jacob D. Estes
SAIC-Frederick, Frederick National Laboratory, Frederick, MD United States of America
Viral dynamics and immune response in acute infection and their impact on viral set-point.
Merlin Robb
Henry M. Jackson Foundation, Bethesda, MD United States of America
Viral evolution in early HIV infection, and the implications for vaccines
Bette Korber
Los Alamos National Laboratory, Los Alamos, NM United States of America
from AIDS Vaccine 2012 on 11 September 2012 8:30 AM-10:00 AM
Oral Abstract 07: B Cell Responses
Structure-Guided Modification and Optimization of Antibody VRC07
Young Do Kwon
National Institutes of Health, Vaccine Research Center, Kensington, MD United States of America
Isolation of a Clonal Lineage of IgA Broadly Neutralizing Antibodies from a Chronically Infected Tanzanian Subject
M Anthony Moody
Duke University Medical Center, Duke Human Vaccine Institute, Durham, NC United States of America
Deep Sequencing with Longitudinal Sampling of a VRC01-Like-Antibody Response in a Chronically Infected Individual
Zhenhai Zhang
Columbia University, Biochemistry and Molecular Biophysics, New York, NY United States of America
Antibody Effector Function Is Regulated by a Combination of Adaptive and Innate Signals
Alison Mahan
Harvard University, Ragon Institute, Charlestown, MA United States of America
Non-neutralizing IgG Anti-PID Antibodies Decreased Viral Load Following High Dose Vaginal Challenge of Non-human Primates
Christiane Moog
INSERM, U748, Strasbourg, France
Vaccine-Induced ADCC-Mediating Antibodies Target Unique and Overlapping Envelope Epitopes
Justin Pollara
Duke University, Durham, NC United States of America
454 Pyrosequencing and Bioinformatics Analysis of the Lineage of the Broad and Potent gp41-Directed Antibody 10e8
Peter D. Kwong
Vaccine Research Center, NIAID, NIH, Bethesda, MD United States of America
Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology.
David Nemazee
The Scripps Research Institute, Immunology and MIcrobial Science, La Jolla, CA United States of America
from AIDS Vaccine 2012 on 11 September 2012 10:30 AM-12:30 PM
Oral Abstract 08: T Cell Responses
Cellular Immune Responses and Changes in VL After a Dendritic Cells (DC)-Based Therapeutic Vaccine in cART Treated Chronic HIV-Infected Patients with
Montserrat Plana
IDIBAPS - Hospital Clinic, Barcelona, Spain
Alterations in Function and Distribution of Regulatory T Cells (Tregs) May Blunt Vaccine Induced Immune Responses in HIV Infection
Julian Schulze zur Wiesch
UKE Hamburg, Germany
Identification of CD8+ T Cell Host Factors Involved in HIV Control
Gaurav Gaiha
Ragon Institute of MGH, MIT and Harvard/Massachusetts General Hospital, Boston, MA United States of America
PD-1, IL-10, IFN-? and IL-12 Form a Network to Regulate HIV-1-Specific CD4 T Cell and Antigen-Presenting Cell Function
Filippos Porichis
Ragon Institute of MGH, MIT and Harvard, Charlestown, MA United States of America
Distinct Gene Expression Profiles Associated with the Susceptibility of Pathogen-Specific CD4+ T Cells to HIV-1 Infection
Haitao Hu
U.S. Military HIV Research Program, Silver Spring, MD United States of America
HIV Control Through a Single Nucleotide on the HLA-I Locus
Henrik Kløverpris
University of Oxford, Oxford, United Kingdom (Great Britain)
Accelerated Heterologous Prime-Boost Adenovirus Vector-Based SIV Vaccine in Neonatal Rhesus Monkeys
Jinyan Liu
Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Vaccine Research, Boston, MA United States of America
Intra-dermal Immunisation with SIV Gag-Based Vaccines Alone Inhibits Acquisition of SIVmac251
Neil Almond
NIBSC-HPA, Retrovirology, Potters Bar, Hertfordshire, United Kingdom (Great Britain)
from AIDS Vaccine 2012 on 11 September 2012 10:30 AM-12:30 PM
Oral Abstract 09: Clinical Trials
Safety and Immunogenicity of a Randomized Phase I Prime-Boost Trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 Adjuvanted in Alum or Polyphosphazene
Robert J. O'Connell
U.S.Military HIV Research Program, Laboratory of Molecular Virology and Pathogenesis, Bethesda, MD United States of America
In Vivo Targeting of HIV Gag to Dendritic Cells in Combination with Poly ICLC Is Safe and Immunogenic in Healthy Volunteers
Marina Caskey
The Rockefeller University, Lab. of Cellular Physiology and Immunology, New York, NY United States of America
First-in-Human Phase 1 Trial of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 5 HVR48 (rAd5HVR48) HIV-1 Vaccine
Stephen R. Walsh
Beth Israel Deaconess Medical Center, Viral Pathogenesis, Boston, MA United States of America
Antibody-Mediated Inhibition of HIV-1 Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults
Agricola Joachim
Muhimbili University of Health and Allied Sciences, Microbiology and Immunology, Dar es Salaam, Tanzania, United Republic of
A First-in-Man, Double Blind, Placebo Controlled Study of the Candidate Therapeutic Vaccine Opal-HIV-Gag(c) in HIV Infected Patients Receiving HAART
Akil G.A. Jackson
St. Stephen's AIDS Trust, London, United Kingdom (Great Britain)
Multiple Antibody Specificities (gp41, V1V2, and V3) Elicited in the Phase II Multiclade (A, B, C) HIV-1 DNA Prime, rAd5 Boost Vaccine Trial
Wilton B. Williams
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC United States of America
rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
Pierre-Alexandre Bart
CHUV, Immunology and Allergy, Lausanne, Switzerland
Phase 2a Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Virus Vaccines Expressing Virus-Like Particles
Paul Goepfert
University of Alabama at Birmignham, Medicine, Birmingham, AL United States of America
from AIDS Vaccine 2012 on 11 September 2012 10:30 AM-12:30 PM
Oral Abstract 10: HIV Transmission / Diversity
Impact of Transmitted CTL Escape Mutations on Replicative Capacity and HIV Pathogenesis in Early Infection
Jessica Prince
Emory University, Atlanta, GA United States of America
A Deeper View of Transmitted/Founder Viruses Using 454 Whole Genome Deep Sequencing
Damien C. Tully
Ragon Institute of MGH, MIT and Harvard, Boston, MA United States of America
Modeling Virus Exposure During Male to Female Transmission of HIV-1
Thomas J. Hope
Northwestern University, Feinberg School of Medicine, Cellular annd Molecular Biology, Chicago, IL United States of America
Beneficial HLA-Mediated Viral Polymorphisms on the Transmitted Virus Additively Influence Disease Progression in HIV-1, Subtype C Infection
Carolyn Williamson
Institute of Infectious Disease and Molecular Medicine, UCT, Clinical Laboratory Sciences , Cape Town, South Africa
T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 Immune Correlate in RV144 Thai Trial
Tomer Hertz
Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention, VIDD, Seattle, WA United States of America
from AIDS Vaccine 2012 on 11 September 2012 1:30 PM-2:45 PM
Oral Abstract 11: Vaccine Immunogens / Delivery
HIV-1 Envelope Trimer Elicits Higher Neutralizing Antibody Responses Than Monomeric gp120
James M. Kovacs
Harvard Medical School and Children's Hospital Boston, Boston, MA United States of America
Shaping Humoral Responses Against Mini-libraries of HIV Env Antigens via Lipid Nanoparticle Vaccine Delivery
Melissa Catherine Hanson
Massachusetts Institute of Technology, Cambridge, MA United States of America
Vaccine Responses to Conserved Regions of the HIV-1 Proteome Are Associated with an Increased Capacity to Inhibit Multiple Virus Isolates Ex Vivo
Ambreen Ashraf
International AIDS Vaccine Initiative (IAVI), Imperial College, London, London, United Kingdom (Great Britain)
Antigen-Specific T Lymphocyte Responses Elicited by a DNA – MVA HIV CN54gp140 Immunization Regime Are Significantly Altered by the TLR4 Adjuvant GLA
Paul F. McKay
Imperial College, Section of Infectious Diseases, Department of Medicine, London, United Kingdom (Great Britain)
Quality of T-cell responses versus reduction in viral load: Results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine
Kim Ellefsen-LaVoi
Centre Hospitalier Universitaire Vaudois (CHUV) Eplainges, Switzerland
from AIDS Vaccine 2012 on 11 September 2012 1:30 PM-2:45 PM
Oral Abstract 12: Vaccine Concepts - Vectors and Inserts
DNA Vaccines Expressing Conserved Elements Provide Potent and Broad Immune Responses
Barbara K. Felber
Frederick National Laboratory for Cancer Research, Frederick, MD United States of America
Reinventing the Nucleic Acid Vaccine with Self-Amplifying RNA
Andrew J. Geall
Novartis Vaccines and Diagnostics, Cambridge, MA United States of America
Adenovirus Serotype 26 Utilizes CD46 as Primary Cellular Receptor and Only Transiently Activates T Lymphocytes Following Vaccination of Rhesus Monkeys
Hualin 0 Li
Beth Israel Deaconess Medical Center, Division of Vaccine Research, Boston, MA United States of America
Full-Length HIV-1 Immunogens Induce Greater T Lymphocyte Responses to Conserved Epitopes Than Conserved-Region-Only HIV-1 Immunogens in Monkeys
Kathryn E. Stephenson
Beth Israel Deaconess Medical Center and Harvard University, Division of Vaccine Research, Boston, MA United States of America
Rational Immunogen Design to Target Specific Germline B Cell Receptors
Joseph Jardine
The Scripps Research Institute, San Diego, CA United States of America
from AIDS Vaccine 2012 on 11 September 2012 1:30 PM-2:45 PM
Symposia 04: Cross-Cutting Issues in Clinical Trial Designs
PrEP and Vaccines: When and How to Respond to Positive Data
Mitchell Warren
AVAC, New York, NY United States of America
Evolving Standards of Prevention and Implications for Future Trials
Douglas R. Wassenaar
SARETI, UKZN, Pietermaritzburg, South Africa
Combination Prevention: Scaling Up Delivery While Accelerating Discovery, Lessons From Medical Male Circumcision in Kenya
Kawango Agot
Impact Research & Development Organization, Kisumu, Kenya
Combination Prevention: Designing and Implementing a New Era of Trials
Ruanne V. Barnabas
University of Washington, Seattle, WA United States of America
Combination Prevention: A Community Perspective on Complex Trial Results and Design
Matthew Rose
Young Black Gay Men's Leadership Initiative, Washington DC, United States of America
Moderated Panel Discussion
from AIDS Vaccine 2012 on 11 September 2012 4:00 PM-6:00 PM
Symposia 05: Mucosal Immunology
Vaccine-microbicide Combination Studies in a Rhesus Macaque Vaginal Transmission Model
John P. Moore
Weill Cornell Medical College, New York, NY United States of America
Genital Tract Inflammation and Susceptibility to HIV Infection in Women from the CAPRISA 004 Microbicide Trial of Tenofovir Gel
Jo-Ann S. Passmore
CAPRISA and University of Cape Town, Cape Town, South Africa
The Current State of Mucosal Immunity Elicited by Vaccines
Robin Shattock
Imperial College London, London, United Kingdom (Great Britain)
Persistence Pays Off: Stringent Control and Potential Clearance of AIDS Virus Infection by Persistent Vaccine-induced Effector Memory T Cells
Louis Picker
Vaccine and Gene Therapy Institute,Oregon Health & Science University, Portland, OR United States of America
HIV Interactions and the Perils of Epithelial Thinning in the Female Reproductive Tract.
Ann Carias
Northwestern University, Chicago, IL United States of America
from AIDS Vaccine 2012 on 11 September 2012 4:00 PM-6:00 PM
Symposia 06: Preclinical Studies and Vaccine Platforms
Novel HIV Vaccine Strategies
Jerald C. Sadoff
Crucell, Leiden, Netherlands
Poxvirus-based Vectors as Immunization Vehicle: Past, Present and Future
Jim Tartaglia
sanofi pasteur, Swiftwater, PA United States of America
Pre-clinical Studies and Vaccine Platforms Using Chimp Adenovirus Vectors
Tomáš Hanke
University of Oxford, The Jenner Institute, Oxford, United Kingdom (Great Britain)
Passive Immunization for HIV Prevention
Francine McCutchan
Bill & Melinda Gates Foundation, Seattle, WA United States of America
E-DNA IM or ID Delivery Prime Enhances Antibody and T Cell Responses Following Recombinant gp120 Env Boost
David B. Weiner
University of Pennsylvania,Pathology and Laboratory Medicine, Philadelphia, PA United States of America
from AIDS Vaccine 2012 on 11 September 2012 4:00 PM-6:00 PM
Symposia 07: Priming Effective B Cell Responses
The Unique T Cell Receptor Expressed by Each Naive Helper T Cell Instructs Effector Cell Fate
Marc K. Jenkins
University of Minnesota, Minneapolis, MN United States of America
T Follicular Helper Cells in HIV Infection
Hendrik Streeck
Ragon Institute of MGH, MIT and Harvard, Boston, MA United States of America
Evolution of Broadly Cross-neutralizing Antibodies During HIV-1 Infection
Penelope L. Moore
National Institute for Communicable Diseases, Johannesburg, South Africa
Genetic and Structural Basis for Development of High Affinity Antibodies
James Crowe
Vanderbilt University, Nashville, TN United States of America
CD40L Adjuvant for DNA/MVA Vaccine: Enhanced Protection from Acquisition of Neutralization Sensitive & Neutralization Resistant Mucosal SIV Infections
Suefen Kwa
Emory University, Microbiology and Immunology, Atlanta, GA United States of America
from AIDS Vaccine 2012 on 12 September 2012 8:30 AM-10:30 AM
Symposia 08: Therapeutic Vaccination and Strategies for the Cure
Therapeutic Approaches to Curing HIV Infection
Steven Deeks
University of California, San Francisco, San Francisco, CA United States of America
Therapeutic Vaccines in Strategies for Functional Cure of HIV
Brigitte Autran
JINSERM U543 - Université Paris VI Pierre et Marie Curie, ORVACS, Paris, France
Barriers to HIV-1 Eradication
Robert Siliciano
Johns Hopkins University School of Medicine, Baltimore, MD United States of America
Persistence of Latently Infected CD4+ T cells During HAART: Keeping Memory, Keeping HIV
Nicolas Chomont
VGTI FL, Port Saint Lucie, FL United States of America
Assembling the Tools to Clear HIV Infection: Contributions from Virology and Immunology
David Margolis
University of North Carolina at Chapel Hill, Chapel Hill, NC United States of America
from AIDS Vaccine 2012 on 12 September 2012 8:30 AM-10:30 AM
Plenary Session 03: New Concepts in Immune Induction
Follicular T helper cells in vaccination and lentivirus pathogenesis
Richard A. Koup
Vaccine Research Center, Bethesda, MD United States of America
Maturation Pathways of Broad Neutralizing Antibodies: Blueprints for Vaccine Design
Bart Haynes
Duke University Medical Center, Durham, NC United States of America
Experimental HIV-vaccines induce immunological memory in murine and human NK cells
Silke Paust
Harvard Medical School, Boston, MA United States of America
from AIDS Vaccine 2012 on 12 September 2012 11:00 AM-12:30 PM
Rapporteurs
The Target: How Do We Hit the Virus Where it Hurts?
Morgane Rolland
MHRP, HJF, Bethesda, MD United States of America
People: Where Do We Stand with Moving Towards Efficacy Trials?
Magdalena Sobieszczyk
Columbia University, New York, NY United States of America
Vaccimunology: Advances in Our Understanding of Immune Correlates
Julie Boucau
The Ragon Institute of MGH, MIT and Harvard, Boston, MA United States of America
Animal Models: What Can Our Furry Friends Teach Us?
Nichole Klatt
National Institute of Health, Bethesda, MD United States of America
from AIDS Vaccine 2012 on 12 September 2012 12:30 PM-1:30 PM
Closing Session
Bill Snow
Global HIV Vaccine Enterprise, New York, NY United States of America
Galit Alter
Conference Chair, Boston, MA United States of America
Dan Barouch
Conference Chair, Boston, MA United States of America
José Gatell
2013 Conference Chair, Barcelona, Spain
Bonaventura Clotet
2013 Conference Chair, Barcelona, Spain
from AIDS Vaccine 2012 on 12 September 2012 1:30 PM-2:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 26 of 26 from AIDS Vaccine 2012